{"id":2930,"date":"2024-04-08T15:05:12","date_gmt":"2024-04-08T13:05:12","guid":{"rendered":"https:\/\/www.institut-myologie.org\/imotion\/?p=2930"},"modified":"2024-04-08T15:17:56","modified_gmt":"2024-04-08T13:17:56","slug":"atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg","status":"publish","type":"post","link":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en","title":{"rendered":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG"},"content":{"rendered":"\n<p>Following several proofs of concept, Atamyo Therapeutics, a spin-off from Geenethon, is to start a new gene therapy trial in patients suffering from limb-girdle muscular dystrophy (LGMD) R5 linked to SGCG (gamma-sarcoglycanopathy). Its aim is to test the safety, pharmacodynamics and efficacy of ATA-200, a product resulting from the work of Isabelle Richard, a researcher at Genethon. Approved to take place in France (<strong>at I-Motion<\/strong>) and Italy, this new multicentre phase I\/II trial will include :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>six walking children aged between 6 and 12 with a clinically and genetically confirmed diagnosis of LGMD R5 ;<\/li>\n\n\n\n<li>two cohorts, each receiving a single intravenous injection of ATA-200, the first at 1 x 1014 vg\/Kg and the second at a dose three times higher;<\/li>\n\n\n\n<li>an assessment of the effects of the product at six months;<\/li>\n\n\n\n<li>follow-up of patients for four and a half years after the evaluation phase.<\/li>\n<\/ul>\n\n\n\n<p>Recruitment is due to begin in May this year, with the first injections scheduled for the third quarter of 2024.<\/p>\n\n\n\n<p>_____<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><a href=\"https:\/\/atamyo.com\/press-releases\/press-releases-2024\/atamyo-therapeutics-obtient-les-autorisations-reglementaires-en-europe-pour-lancer-lessai-clinique-de-ata-200-sa-therapie-genique-pour-traiter-la-myopathie-des-ceintures-lgmd-2c-r5\/\" target=\"_blank\" rel=\"noreferrer noopener\"><em>Atamyo Therapeutics obtient les autorisations r\u00e9glementaires en Europe pour lancer l\u2019essai clinique de ATA-200, sa th\u00e9rapie g\u00e9nique pour traiter la myopathie des ceintures&nbsp;LGMD-2C\/R5.<\/em><\/a> Atamyo Therapeutics. 26 March 2024 press release.<\/p>\n\n\n\n<p>On Clinicaltrials.gov website: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05973630\" target=\"_blank\" rel=\"noreferrer noopener\">NCT05973630<\/a>.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Following several proofs of concept, Atamyo Therapeutics, a spin-off from Geenethon, is to start a new gene therapy trial in patients suffering from limb-girdle muscular dystrophy (LGMD) R5 linked to SGCG (gamma-sarcoglycanopathy). Its aim is to test the safety, pharmacodynamics and efficacy of ATA-200, a product resulting from the work of Isabelle Richard, a researcher &hellip; <a href=\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\">Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[15,3],"tags":[],"class_list":["post-2930","post","type-post","status-publish","format-standard","hentry","category-clinical-news","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion\" \/>\n<meta property=\"og:description\" content=\"Following several proofs of concept, Atamyo Therapeutics, a spin-off from Geenethon, is to start a new gene therapy trial in patients suffering from limb-girdle muscular dystrophy (LGMD) R5 linked to SGCG (gamma-sarcoglycanopathy). Its aim is to test the safety, pharmacodynamics and efficacy of ATA-200, a product resulting from the work of Isabelle Richard, a researcher &hellip; Continued\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\" \/>\n<meta property=\"og:site_name\" content=\"I-Motion\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-08T13:05:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-08T13:17:56+00:00\" \/>\n<meta name=\"author\" content=\"Anne Berthomier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Berthomier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\"},\"author\":{\"name\":\"Anne Berthomier\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\"},\"headline\":\"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG\",\"datePublished\":\"2024-04-08T13:05:12+00:00\",\"dateModified\":\"2024-04-08T13:17:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\"},\"wordCount\":219,\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"articleSection\":[\"Clinical News\",\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\",\"name\":\"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\"},\"datePublished\":\"2024-04-08T13:05:12+00:00\",\"dateModified\":\"2024-04-08T13:17:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.institut-myologie.org\/imotion\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"name\":\"I-Motion\",\"description\":\"Plateforme d&#039;essais cliniques p\u00e9diatriques pour les maladies neuromusculaires\",\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\",\"name\":\"Institut I-Motion\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"contentUrl\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"width\":150,\"height\":51,\"caption\":\"Institut I-Motion\"},\"image\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\",\"name\":\"Anne Berthomier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"caption\":\"Anne Berthomier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en","og_locale":"fr_FR","og_type":"article","og_title":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion","og_description":"Following several proofs of concept, Atamyo Therapeutics, a spin-off from Geenethon, is to start a new gene therapy trial in patients suffering from limb-girdle muscular dystrophy (LGMD) R5 linked to SGCG (gamma-sarcoglycanopathy). Its aim is to test the safety, pharmacodynamics and efficacy of ATA-200, a product resulting from the work of Isabelle Richard, a researcher &hellip; Continued","og_url":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en","og_site_name":"I-Motion","article_published_time":"2024-04-08T13:05:12+00:00","article_modified_time":"2024-04-08T13:17:56+00:00","author":"Anne Berthomier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Anne Berthomier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#article","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en"},"author":{"name":"Anne Berthomier","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def"},"headline":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG","datePublished":"2024-04-08T13:05:12+00:00","dateModified":"2024-04-08T13:17:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en"},"wordCount":219,"publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"articleSection":["Clinical News","Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en","url":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en","name":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG - I-Motion","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#website"},"datePublished":"2024-04-08T13:05:12+00:00","dateModified":"2024-04-08T13:17:56+00:00","breadcrumb":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.institut-myologie.org\/imotion\/2024\/04\/08\/atamyo-therapeutics-obtains-authorisation-to-launch-a-gene-therapy-clinical-trial-in-limb-girdle-muscular-dystrophy-linked-to-sgcg\/?lang=en#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.institut-myologie.org\/imotion\/"},{"@type":"ListItem","position":2,"name":"Atamyo Therapeutics obtains authorisation to launch a gene therapy clinical trial in limb-girdle muscular dystrophy linked to SGCG"}]},{"@type":"WebSite","@id":"https:\/\/www.institut-myologie.org\/imotion\/#website","url":"https:\/\/www.institut-myologie.org\/imotion\/","name":"I-Motion","description":"Plateforme d&#039;essais cliniques p\u00e9diatriques pour les maladies neuromusculaires","publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization","name":"Institut I-Motion","url":"https:\/\/www.institut-myologie.org\/imotion\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/","url":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","contentUrl":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","width":150,"height":51,"caption":"Institut I-Motion"},"image":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def","name":"Anne Berthomier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","caption":"Anne Berthomier"}}]}},"_links":{"self":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/comments?post=2930"}],"version-history":[{"count":3,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2930\/revisions"}],"predecessor-version":[{"id":2939,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2930\/revisions\/2939"}],"wp:attachment":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/media?parent=2930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/categories?post=2930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/tags?post=2930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}